Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials

Status: Recruiting
Phase: N/A
Diagnosis: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
NCT ID: NCT00487513 (View complete trial on
DFCI Protocol ID: 06-276


In order to learn more about follicular lymphoma and anti-cancer vaccines, we are collecting samples from people with this diagnosis. We then hope to make a vaccine from this tissue to help the immune system destroy cancer cells. We plan on keeping samples in the tissue bank indefinitely.


Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital

Overall PI:
Eric Jacobsen, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Dana-Farber Cancer Institute: Nicole Gallo, 617-582-7970,

Eligibility Criteria

Inclusion Criteria: - Relapsed, refractory or de novo histologically confirmed follicular B-cell lymphoma with accessible lymph nodes, tumor mass or malignant effusion or peripheral blood - 40 years of age or older Exclusion Criteria: - Uncontrolled active infection - HIV or viral Hepatitis infection - Other current malignancies except any in situ cancer or basal or squamous cell carcinoma of the skin - Autoimmune cytopenias
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Request Appointment Online